These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35561263)

  • 21. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
    Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
    Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
    Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.
    Ozga M; Huang Y; Blachly JS; Grieselhuber NR; Wall S; Larkin K; Haque T; Walker AR; Bhatnagar B; Behbehani G; Vasu S; Maakaron JE; Lustberg M; Mims AS
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e76-e83. PubMed ID: 32921593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
    White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
    J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
    Aldoss I; Dadwal S; Zhang J; Tegtmeier B; Mei M; Arslan S; Al Malki MM; Salhotra A; Ali H; Aribi A; Sandhu K; Khaled S; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Blood Adv; 2019 Dec; 3(23):4043-4049. PubMed ID: 31816059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
    Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
    J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
    Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
    Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
    Tüfekçi Ö; Yılmaz Bengoa Ş; Demir Yenigürbüz F; Şimşek E; Karapınar TH; İrken G; Ören H
    Turk J Haematol; 2015 Dec; 32(4):329-37. PubMed ID: 25913290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.
    Rosanova MT; Bes D; Serrano Aguilar P; Sberna N; Lede R
    Infect Dis (Lond); 2018 Jul; 50(7):489-494. PubMed ID: 29262742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
    Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
    Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.
    Martino R; Garrido A; Santaliestra M; García-Cadenas I; Novelli S; Saavedra SD; Esquirol A; Granell M; Briones J; Moreno C; Brunet S; Giménez A; Hidalgo A; Sánchez F; Sierra J
    Mycopathologia; 2020 Aug; 185(4):639-652. PubMed ID: 32564177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D-index and invasive fungal infections (IFIs) in adult acute myeloid leukemia (AML) patients with the first episode of febrile neutropenia.
    Rattanathammethee T; Munsamai K; Punnachet T; Hantrakun N; Piriyakhuntorn P; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
    PLoS One; 2023; 18(5):e0286089. PubMed ID: 37216345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.